This was in accordance with several preclinical studies which enrolled a panel of different lung cancer cell lines treated with chemotherapy/EGFR-TKI and reported that the sequence of chemotherapy→EGFR-TKI had advantage over other modalities [8], [9], [15]. This evidence concerns the gene EGFR and lung carcinoma.